1. Introduction {#sec1}
===============

The triggering events in rheumatoid arthritis (RA), especially the identity of the primary autoantigen(s), await conclusive characterization. Nonetheless, it is well recognized that ongoing inflammation of the peripheral joints with accompanying tissue damage involves complex, cytokine-driven interactions between resident synovial and infiltrating inflammatory cells \[[@B1]--[@B3]\], particularly T-helper 1 (Th1) cells of the effector-memory phenotype \[[@B4]--[@B6]\]. Recent studies have suggested that chronic inflammation in the rheumatoid joint may result from the sustained activation/dysregulation of inflammatory cytokine networks which operate independently of triggering autoantigens and T-cell receptor (TCR) ligation \[[@B7]--[@B9]\]. In this setting, two mechanisms, probably interactive, have been identified which appear to maintain autoantigen-independent production of inflammatory cytokines. These are (i) direct activation of a subset of effector-memory Th1 cells by cytokines signaling via the interleukin-2 receptor (IL-2R) common *γ*-chain in combination with IL-12 and IL-18, with resultant generation of interferon-*γ* (IFN-*γ*) \[[@B10], [@B11]\] and (ii) continuous activation of immune and inflammatory cells, including Th1 cells, via interaction of Toll-like receptors (TLRs) with extracellular matrix components released from damaged host tissues \[[@B12]--[@B15]\].

Because of the critical role of cytokine networks in perpetuating inflammatory responses in the rheumatoid joint, circulating, and/or synovial cytokines are considered to be ideal biomarkers to monitor disease onset, development and progression, either directly using cytokine multiplex immunoassays or indirectly by gene profiling approaches \[[@B16]--[@B20]\]. To date, however, relatively few studies have been reported in which circulating cytokine profiles have been used either as a strategy to predict disease severity and outcome in RA, or to provide insights into immunopathogenesis. Those which have been described have consistently documented significant elevations in the concentrations of a range of circulating proinflammatory cytokines \[[@B16], [@B21]--[@B25]\]. Nevertheless, these studies need to be corroborated and extended in larger groups of patients not only to establish circulating cytokine profiles in RA, but also to identify inter-relationships between cytokines of different cellular origins and their associations with conventional biomarkers and clinical markers of disease activity, and their predictive potential.

In the current study, we have measured the concentrations of a range of circulating anti-inflammatory and proinflammatory cytokines in a relatively large cohort (*n* = 140) of predominantly African patients with early, disease modifying antirheumatic drug-naïve RA. Vascular endothelial growth factor (VEGF), which is produced by both macrophages and fibroblasts \[[@B26], [@B27]\], and which appears to correlate with disease activity and progression \[[@B28], [@B29]\], was included in the multiplex analysis.

2. Patients and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

A cohort of 140 patients, who met the 1987 American College of Rheumatology criteria for RA \[[@B30]\], were disease-modifying antirheumatic drug (DMARD) naïve, had disease duration of ≤2 years, and seen at two tertiary hospitals in South Africa, were studied. All patients were HIV-negative and receiving treatment with either diclofenac (majority) or naproxen at the time of recruitment. The 28-joint disease activity score-CRP 28 (DAS28-CRP) \[[@B31], [@B32]\] and modified Health Questionnaire Disability Index (HAQ-DI) \[[@B33]\] were documented. Clinically, high disease activity (HDA) was defined as DAS28 ≥ 5.1 (*n* = 63) and moderate disease activity (MDA) as a DAS28 ≥ 3.2 -- \< 5.1 (*n* = 62) \[[@B34]\]. Erosive disease was defined as the presence of marginal joint erosions on plain X-rays of the hands and feet. The study was approved by the Research Ethics Committees of the Faculties of Health Sciences of the University of Pretoria and University of the Witwatersrand.

2.2. Laboratory Methods {#sec2.2}
-----------------------

Venous blood (30 mL) was collected in endotoxin-free, silicone-coated vacutainers containing a gel separator. The blood samples were allowed to stand at room temperature to coagulate (\<1 hour) followed by centrifugation (3000 rpm for 10 minutes) after which the serum was removed, aliquoted, and stored at minus 20°C until performance of the various assays described below.

### 2.2.1. Autoantibodies and Acute Phase Reactants {#sec2.2.1}

Rheumatoid factor (composite IgM, IgG, IgA), CRP, and SAA were assayed by nephelometry (Siemens Healthcare Diagnostics, BN Prospec Nephelometer, Newark, USA). As per supplier controls, RF, CRP, and SAA results were considered positive when the concentrations were greater than 11 IU/mL, 5 *μ*g/mL and 6.8 *μ*g/mL, respectively. Anticyclic citrullinated peptide antibodies (aCCP) were measured by an immunofluorometric procedure using the Immunocap 250 system and reagents and controls provided by the manufacturer (Phadia AB, Uppsala, Sweden), and a concentration \>10 U/mL was deemed positive. Antimodified citrullinated vimentin antibodies (aMCV) were measured using an ELISA assay (Orgentec Diagnostika GmbH, Mainz, Germany), and a concentration \>20 U/mL was deemed positive.

### 2.2.2. Serum Cytokines, Chemokines, and Growth Factors {#sec2.2.2}

These were measured using the Bio-Plex suspension array system (Bio-Rad Laboratories Inc, Hercules, CA, USA) which utilizes Luminex xMAP multiplex technology to enable simultaneous detection and quantitation of multiple different analytes in a single sample. The system uses an array of microspheres in liquid suspension, conjugated with a monoclonal antibody specific for a target protein. The beads contain different ratios of two spectrally distinct fluorophores, thereby assigning a unique spectral identity. These antibody-coupled, colour-coded beads were then incubated with the serum sample (1/4 dilution), washed, followed by addition of a biotinylated detection antibody, washed again, and finally incubated with streptavidin-phycoerythrin. A wide range of standards (0.38--91756.00 pg/mL) was used to enable quantitation of the individual cytokines using a Bio-Plex array reader with a dual laser detector and real-time digital signal processing. The following analytes were measured simultaneously using a 17-plex test kit: IL-1*β*, IL-1Ra, Il-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17A, IFN-*γ*, TNF, G-CSF, GM-CSF, CCL2, CCL4, and VEGF, broadly representative of Th1/Th2/Th17, and macrophage/fibroblasts. The upper limit of normal for these analytes was calculated as the mean + 1SD for 10 healthy control subjects (5 female, 5 male, average age 44.4 ± 15.0 years, ranging from 26--65 years of age).

### 2.2.3. Statistical Methods {#sec2.2.3}

Statistical Analysis was performed using STATA statistical software. Correlation coefficients were derived from correlation matrices using the nonparametric Spearman\'s rank correlation test with Holm\'s method *P* value correction for multiple testing. A *P* value \<  .05 was considered as significant.

3. Results {#sec3}
==========

3.1. Demographic, Clinical, and Laboratory (Autoantibodies, Acute Phase Reactants) Data {#sec3.1}
---------------------------------------------------------------------------------------

These are shown in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} for the total cohort and the MDA and HDA subgroups, respectively. RF, aCCP, and aMCV were positive in 79%, 79%, and 74% of RA patients, respectively, while CRP and SAA levels were raised in 71% and 68% of patients, respectively. The mHAQ-DI did not correlate with any of the laboratory parameters or DAS28, while the DAS28 score correlated with CRP and SAA (*r* = 0.52 and *r* = 0.42, resp., *P* \< .0001 for both), in keeping with Emery et al. \[[@B35]\] Not surprisingly, aCCP and aMCV were strongly correlated (*r* = 0.76, *P* \< .0001) as were CRP and SAA (*r* = 0.82, *P* \< .0001), while only weak correlations were detected between these autoantibodies and the acute phase reactants. RF correlated moderately with aCCP and aMCV (*r* = 0.51, *P* = .0002 and *r* = 0.44, *P* = .0014, resp.), and weakly with CRP and SAA (*r* = 0.2, *P* \< .02 for both).

3.2. Circulating Cytokines, Chemokines, and Growth Factors in Healthy Controls and RA Patients {#sec3.2}
----------------------------------------------------------------------------------------------

With the exception of TNF, IL-12, G-GSF, and VEGF (mean values of 21 ± 3, 34 ± 37, 34 ± 16, and 176 ± 189 pg/mL, resp.), the mean circulating concentrations of all the other cytokines ranged from 0--6 pg/mL in the group of healthy subjects with no meaningful differences between males and females. The results for the total cohort of RA patients, as well as for the MDA and HDA subgroups are shown in Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}, respectively. The serum concentrations of the cytokines, chemokines and growth factors were significantly elevated in the total RA cohort, relative to those of the healthy control subjects, and those previously reported for healthy adult humans \[[@B36]\], although the spread of values for each cytokine was considerable. The only exception was IL17A, for which only very modest elevations were evident. No significant differences were observed between the MDA and HDA groups.

3.3. Correlations between Cytokines/Chemokines/Growth Factors {#sec3.3}
-------------------------------------------------------------

These results are shown in [Table 5](#tab5){ref-type="table"} with strong correlations highlighted in bold type and moderate and weak correlations in plain type. Moderate-to-strong correlations between cytokines of Th1 cell (IL-2, IFN-*γ*, GM-CSF), Th2 cell (IL-4, IL-6, IL-10), monocyte/macrophage (IL-1*β*, IL-6, IL-12, TNF, G-CSF), and fibroblast (IL-7) origin were observed in the total cohort of RA patients. Of the chemokines, only CCL2 was moderately correlated with the Th1/Th2/macrophage/fibroblast cytokines (*r* = 0.46--0.66, *P* ≤ .0001--.0007). VEGF, perhaps not surprisingly, given its probable fibroblast and macrophage origins \[[@B26], [@B27]\], correlated best with IL-7 (*r* = 0.55, *P* \< .0001) and IL-12 (*r* = 0.45, *P* = .0009), but only weakly or not at all with other cytokines.

3.4. Correlations with RF, aCCP, and aMCV {#sec3.4}
-----------------------------------------

These results are shown in [Table 6](#tab6){ref-type="table"} for the total cohort of RA patients. RF correlated moderately with IL-1*β*, IL-4, IL-7, IL-12, G-CSF, GM-CSF, IFN-*γ*, and TNF and weakly-to-moderately with IL-Ra, IL-2, IL-6, IL-8, IL-10, IL17A, VEGF, CCL2, and CCL4. Similar, albeit somewhat weaker, correlations were observed between these same cytokines and aCCP and aMCV antibodies. In the case of the acute phase reactants, IL-6, not surprisingly, was found to correlate moderately with CRP and SAA (*r* = 0.49 and 0.52, resp., *P* \< .0001 for both), while weak or no correlations were noted with the other cytokines (not shown).

Interestingly, VEGF which correlated only weakly with the Th1/Th2/macrophage/fibroblast cytokines in the total cohort demonstrated considerably stronger correlations with these cytokines in the HDA subgroup. In this subgroup, but not in the total cohort, strong and significant correlations of VEGF with RF, aCCP, and aMCV were also evident as well as a weak correlation with X-ray (Larsen) scores as shown in [Table 7](#tab7){ref-type="table"}.

3.5. Associations of the DAS28 Clinical Scores in the Total Cohort of Patients and the HDA and MDA Subgroups with Circulating Biomarkers of Disease Activity {#sec3.5}
------------------------------------------------------------------------------------------------------------------------------------------------------------

No significant relationships were evident between the DAS28 scores, disease activity and any of the serum cytokines, chemokines, and growth factors in the total RA cohort or the MDA subgroup (data not shown). In the HDA subgroup, however, DAS28 scores, but not disease duration, showed significant correlations with serum IFN-*γ* (*r* = 0.49, *P* = .0160), IL-1*β* (*r* = 0.52, *P* = .0088), IL-1Ra (*r* = 0.62, *P* = .0013), TNF (*r* = 0.58, *P* = .0033), and GM-CSF (*r* = 0.58, *P* = .0033).

4. Discussion {#sec4}
=============

Multiplex analysis of circulating cytokines in RA has the potential not only to provide novel insights into the immunopathogenesis of RA, but also to identify subgroups of patients at risk for development of severe disease. To date, however, this important topic has been addressed in a limited number of studies \[[@B16], [@B19], [@B20], [@B22]--[@B25], [@B37]\]. These have shown promise, particularly two recent studies which have described generalised elevations in circulating cytokines, especially Th1/Th2/macrophage cytokines, which precede the onset of clinical disease and are also markers of disease severity \[[@B20], [@B37], [@B38]\]. However, there is clearly a need for corroboration and extension in larger groups of patients. In the current study, we have investigated circulating cytokine profiles, representative of Th1, Th2, and Th17 cells, monocytes/macrophages, and fibroblasts, in a large group of DMARD-naïve RA patients of disease duration \<2 years. Notwithstanding characterization of circulating cytokine profiles, the major objectives of the current study were to identify inter-relationships between cytokines, as well as correlations with RA-associated autoantibodies, acute phase reactants, and clinical disease activity. These were analysed in the total cohort of patients, as well as in the MDA and HDA subgroups.

In the case of the total cohort, and in keeping with previous studies \[[@B16], [@B19], [@B20], [@B22]--[@B25], [@B37]\], we observed a general increase in the circulating levels of all of the anti-inflammatory/proinflammatory cytokines, growth factors and chemokines. IL17A was the exception, being barely detectable and only modestly intercorrelated with the other cytokines. In contrast, cytokines primarily of Th1 and Th2 lymphocyte origin, as well as those derived mainly from monocytes/macrophages and fibroblasts, were not only elevated, but also highly intercorrelated in the total cohort, and strongest in the HDA subgroup. The strong correlations of the Th2 cytokines, IL-4, and IL-10 \[[@B39]\], with those of the proinflammatory cytokines, IL-1*β*, IL-2, IL-6, IL-7, IL-12, G-CSF, GM-CSF, IFN-*γ*, and TNF, probably reflect the efforts of these cells to suppress the reactivity of their Th1 counterparts, and to redirect the phenotype and functions of classically IFN-*γ*-activated M1 macrophages \[[@B40], [@B41]\]. It is, however, noteworthy that IL-10 also originates from cell types other than Th2 cells, and M2-derived IL-10 is also likely to fulfill an anti-inflammatory function underscoring the plasticity of transitions between various cell phenotypes according to the cytokine environment. Notwithstanding its anti-inflammatory activity, IL-4 may also play a proinflammatory role in RA by driving the activity of autoreactive B cells, possibly underscored by the associations of IL-4 with aCCP and aMCV. In addition to effects on Th1 cells and M1 macrophages, the Th2 cytokines IL-4 and IL-10 also suppress the proliferation and proinflammatory activities of fibroblasts \[[@B42]--[@B45]\]. Importantly, the consistency and magnitude of the correlations between the cytokines suggest that these are unlikely to be spurious, and also attest to the robustness of the multiplex cytokine assay system. Although our group of healthy control subjects was relatively small (*n* = 10), their low levels of circulating cytokines are comparable with those reported from a much larger series of healthy subjects \[[@B36]\].

In keeping with the increasing recognition of the involvement of IL-7 in orchestrating chronic inflammation in the rheumatoid joint \[[@B46]--[@B50]\], this cytokine was found to be highly correlated with IL-12 in particular, as well as with IFN-*γ*. Synovial fibroblasts, activated by IL-1*β* and TNF, as well as macrophages, are likely to be the major source of IL-7. Interestingly, the predominant lymphocyte subset in the rheumatoid joint has been reported to be of the Th1 effector-memory phenotype, expressing functional IL-12R, IL-18 R*α*, and CCR5 \[[@B11]\]. These cells are directly activated to secrete IFN-*γ* by cytokines such as IL-2, IL-7, and IL-15, but not IL-4, which signal via the IL-2R common *γ*-chain in combination with IL-12 and IL-18, independently of TCR ligation \[[@B11]\]. Although of considerable interest, further studies are necessary to confirm the role of this autoantigen-independent mechanism of perpetuation of inflammation in RA.

Circulating IFN-*γ* was strongly correlated with the predominantly macrophage-derived cytokines IL-1*β*, IL-12, TNF, and G-CSF. This is in keeping with the classically, IFN-*γ*-activated macrophage of the M1 phenotype being a major source of proinflammatory cytokines in the inflamed RA joint \[[@B51]\]. Of the 3 chemokines measured, IL-8, CCL2, and CCL4, only CCL2 showed moderate correlations with the various Th1/Th2, macrophage and fibroblast cytokines, in the total cohort, possibly reflecting the predominantly macrophage/fibroblast origins of this monocyte-targeted chemokine.

Circulating VEGF, which has been reported to predict disease severity and progression in RA \[[@B28], [@B29], [@B52]\], correlated poorly with the other cytokines with the exceptions of IL-7 in particular, and IL-12, possibly reflecting the fibroblast and macrophage origins, respectively, of VEGF \[[@B26], [@B27]\]. However, when the total cohort of RA patients was subdivided into those with MDA and HDA, significant correlations were observed between VEGF and the Th1/Th2/macrophage/fibroblast cytokines, as well as with RF, aCCP, and aMCV in the HDA group, substantiating the role of VEGF as a predictor of severity of disease in our cohort.

With respect to correlations of the Th1, Th2, Th17, monocyte/macrophage, and fibroblast cytokines, with traditional biomarkers of disease activity in the total cohort, RF correlated moderately with IL-1*β*, IL-4, IL-7, IL-12, G-CSF, GM-CSF, IFN-*γ*, and TNF, with weaker, but nonetheless significant correlations detected between these same cytokines, and aCCP and aMCV. Not surprisingly, the acute phase reactants, CRP and SAA, correlated best with IL-6, while weak correlations were evident with most of the other cytokines. Given the strong association of RF, aCCP, and aMCV with disease severity and poor prognosis in RA \[[@B53]--[@B56]\], these findings are compatible with the involvement of the Th1 lymphocyte/macrophage/fibroblast axis in the immunopathogenesis of RA \[[@B5], [@B57]\]. This contention is underscored by the significant correlations of IL-1*β*, IL-1Ra, TNF, IFN-*γ*, and GM-CSF with the DAS28 score observed in the HDA subgroup. Although a role for Th2 cells in disease pathogenesis cannot be excluded, the association of the Th2 cytokines, IL-4, and IL-10, with RF, aCCP, and aMCV most likely reflects their anti-inflammatory activities. A dynamic interaction between the production of Th1 and Th2 cytokines with opposing pro- and anti-inflammatory activities may regulate the rate and severity of damage to cartilage and bone in established RA. This in turn may explain the relatively weak correlations of acute phase reactants with cytokines and autoantibodies.

Transiently elevated concentrations of cytokine in synovial fluid have been reported with certain cytokines of T cell, macrophage, and stromal cell origin being elevated in early disease, but apparently undetectable in established disease \[[@B58]\]. The inflamed synovium is infiltrated by pathogenic effector T cells and autoreactive B cells activated by unknown triggers where they orchestrate local joint inflammation. It has been clearly demonstrated that the elevated synovial, as well as circulating cytokines, are a common manifestation of the persistent state of inflammation and are predictive of disease severity \[[@B1], [@B16], [@B20], [@B24], [@B38], [@B58]--[@B62]\].

The limitations of the current study include our focus on circulating, as opposed to synovial cytokines \[[@B63]\], as well as the recruitment of patients with established, rather than very early disease. In defence of these strategies, measurement of synovial cytokines presents logistical and ethical issues and is relatively impractical from a laboratory diagnostic perspective, while identification of patients with very early disease is particularly difficult in the health care setting of a developing country. The strengths of the study, on the other hand, include the relatively large number of patients recruited to the study, all of whom were DMARD-naïve, as well as the range of circulating markers of disease activity which were evaluated.

In conclusion, the current study has demonstrated a circulating cytokine profile in patients with established RA which appears compatible with Th1 cell/macrophage/fibroblast activation and a possible counter-regulatory role of Th2 cells. This is underscored by relatively strong correlations between cytokines and established biomarkers, especially RF, as well as aCCP and aMCV antibodies. IL-1*β*, IL-1Ra, TNF, IFN-*γ*, GM-CSF, and VEGF in particular were significantly associated with HDA and show promise as adjunctive diagnostic/prognostic biomarkers, either individually or in combination. The clinical utility of this strategy will, however, depend on the outcome of large, multicentre follow-up studies.
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###### 

Demographic, laboratory, and clinical data for the group of RA patients (*n* = 140).

  Parameters                                            Quintiles          
  ------------------------------- --------------- ----- ----------- ------ ----------
  Age (years)                     48 ± 12         41    48          56     20--75
  Female (%)                      115 (82.1)                               
  Ethnic origin: Black (%)        111 (87.0)                               
  DAS28-CRP                       5.7 ± 1.2       4.8   5.9         6.6    2.3--8.0
  HDA (DAS28 ≥ 5.1) (%)           63 (45.0)                                
  LDA (DAS28 ≥ 3.2 & \<5.1) (%)   62 (44.3)                                
  mHAQ-DI                         3.2 ± 1.6       2.0   3.5         4.5    0.0--6.0
  Disease duration (months)       12 ± 7          6     10          18     0--25
  SJC                             10 ± 6          4     9           14     0--27
  X-ray erosions (%)              65/121 (53.7)                            
  RF (IU/mL)                      493 ± 803       40    171         579    4--5350
  aCCP (U/mL)                     654 ± 621       80    490         1082   2--2431
  aMCV (U/mL)                     594 ± 679       104   326         775    16--3088
  CRP (mg/L)                      23.0 ± 2.5      5.1   13.6        30.6   0.3--164
  SAA (*μ*g/mL)                   61 ± 124        5     16          60     1--882

DAS28: Disease activity score for 28 joints, HDA: High disease activity, LDA: Low disease activity, mHAQ-DI: modified Health assessment questionnaire-disease Index, SJC: Swollen Joint Count, RF: Rheumatoid factor, aCCP: anticyclic citrullinated peptide antibodies, aMCV: Antimodified citrullinated vimentin antibodies, CRP: C-reactive protein, SAA: Serum amyloid A.

###### 

Demographic, laboratory, and clinical data for the LDA (*n* = 62) and HDA (*n* = 63) groups of RA patients.

  Parameters                                     MDA                                        HDA          
  --------------------------- ------------ ----- ----- ------ ---------- ------------ ----- ----- ------ ----------
  Age (years)                 46 ± 10      41    45    53     22--68     49 ± 12      45    50    57     20--75
  Female (%)                  47 (75)                                    50 (80)                         
  Ethnicity: Black (%)        48 (78)                                    59 (94)                         
  DAS28-CRP                   4.5 ± 0.5    4.3   4.7   4.8    3.3--5.0   6.5 ± 0.6    6.2   6.6   6.9    5.2--8.7
  mHAQ-DI                     3.3 ± 1.7    2.0   3.6   4.5    0.0--6.0   1.8 ± 0.8    1.3   2.1   2.4    0.0--3.0
  Disease duration (months)   13 ± 8       7     11    20     2--24      11 ± 8       5     9     18     2--24
  SJC                         5 ± 3        3     5     7      0--15      14 ± 6       10    13    17     4--28
  X-ray erosions (%)          28/53 (53)                                 29/57 (51)                      
  RF (IU/mL)                  480 ± 681    57    177   559    4--2860    491 ± 812    21    178   654    10--5350
  aCCP (U/mL)                 618 ± 639    51    343   1001   2--2026    734 ± 667    89    599   1213   2--2527
  aMCV (U/mL)                 597 ± 731    90    319   710    20--3028   638 ± 727    108   334   868    16--3088
  CRP (mg/L)                  8 ± 10       2     5     8      1--40      36 ± 38      10    27    37     0--198
  SAA (*μ*g/mL)               25 ± 48      2     5     24     1--238     91 ± 153     8     35    124    1--882

DAS28: Disease activity score for 28 joints, HDA: High disease activity, LDA: Low disease activity, mHAQ-DI: modified Health assessment questionnaire-disease Index, SJC: Swollen Joint Count, RF: Rheumatoid factor, aCCP: anticyclic citrullinated peptide antibodies, aMCV: Antimodified citrullinated vimentin antibodies, CRP: C-reactive protein, SAA: Serum amyloid A.

###### 

Serum cytokine, chemokine, and growth factor values for the total RA cohort *n* = 140.

            Mean ± SD\*    Q1(p25)\*   Q2 (Median)\*   Q3 (p75)\*   Range\*
  --------- -------------- ----------- --------------- ------------ ----------
  IL-1*β*   24.8 ± 48      1.4         5.3             20.0         0--269
  IL-Ra     363.5 ± 793    25.3        74.8            266.1        0--5012
  IL-2      44.7 ± 155     0.0         0.0             30.2         0--1320
  IL-4      30.5 ± 84      0.1         3.6             13.3         0--598
  IL-6      64.7 ± 130     6.8         18.3            65.5         0--1078
  IL-7      221.1 ± 741    4.9         22.2            89.5         0--6825
  IL-8      295.5 ± 3111   5.0         9.3             20.2         0--36699
  IL-10     41.6 ± 134     3.9         10.7            25.8         0--1172
  IL-12     123.9 ± 404    2.2         11.0            54.3         1--3105
  IL-17A    6.0 ± 26       0.0         0.0             0.26         0--229
  G-CSF     226.9 ± 842    0.0         14.3            57.9         0--8764
  GM-CSF    112.8 ± 375    0.0         0.0             31.0         0--3726
  IFN-*γ*   580.1 ± 1588   0.0         31.3            195.5        0--10922
  CCL2      89.0 ± 200     0.0         50.7            107.4        0--1771
  CCL4      132.6 ± 94     70.4        108.2           171.7        27--544
  TNF       149.6 ± 434    4.3         11.6            61.9         1--2952
  VEGF      450.4 ± 712    59.4        166.4           518.8        0--4503

\*results in pg/mL.

###### 

Circulating cytokine data for the MDA (*n* = 62) and HDA (*n* = 63) groups of RA patients..

            MDA          HDA                                                       
  --------- ------------ ----- ----- ----- --------- ------------ ---- ----- ----- ----------
  IL-1*β*   19 ± 29      3     4     26    0--122    30 ± 60      1    5     17    0--269
  IL-1Ra    291 ± 495    28    73    266   0--2994   429 ± 973    26   90    252   0--5012
  IL-2      33 ± 88      0     0     31    0--516    33 ± 68      0    0     27    0--297
  IL-4      33 ± 75      0     5     15    0--361    20 ± 0.46    0    3     11    0--254
  IL-6      51 ± 79      6     16    60    0--309    73 ± 120     11   27    86    0--792
  IL-7      160 ± 476    5     21    95    0--3324   282 ± 954    7    23    78    0--6852
  IL-8      54 ± 167     5     9     18    0--997    612 ± 4620   8    11    23    0--36699
  IL-10     35 ± 82      3     11    22    0--472    51 ± 178     6    10    27    0--1172
  IL-12     172 ± 401    2     11    48    1--226    117 ± 407    3    13    64    1--3105
  IL-17A    8 ± 37       0     0     0     0--229    3 ± 9        0    0     0     0--46
  IFN-*γ*   585 ± 1444   3     48    350   0--7541   527 ± 1330   0    27    160   0--6431
  G-CSF     181 ± 461    1     16    55    0--2285   179 ± 423    0    7     64    0--1664
  GM-GSF    87 ± 211     0     0     24    0--1048   101 ± 236    0    0     41    0--978
  TNF       161 ± 452    5     11    54    1--2952   131 ± 392    5    12    69    1--2665
  VEGF      475 ± 769    54    139   513   0--3582   419 ± 502    70   198   534   9--2196
  CCL2      69 ± 85      0     41    109   0--417    112 ± 276    14   55    103   0--1771
  CCL4      117 ± 64     68    95    163   27--291   159 ± 116    89   119   199   32--643

Values in pg/mL.

###### 

Correlations between the serum cytokines, chemokines, and growth factor concentrations in the total cohort of RA patients (*n* = 140).

                IL-1*β*       IL-1Ra        IL-2          IL-4       IL-6          IL-7       IL-8          IL-10         IL-12      IL-17         G-CSF         GM-CSF        IFN-*γ*
  ------------- ------------- ------------- ------------- ---------- ------------- ---------- ------------- ------------- ---------- ------------- ------------- ------------- ----------
  TNF           **0.85**      0.64          **0.77**      **0.86**   0.59          0.50       0.23          0.70          0.68       0.52          **0.75**      **0.79**      **0.81**
  **\<.0001**   \<.0001       **\<.0001**   **\<.0001**   \<.0001    \<.0001       .0062      \<.0001       \<.0001       \<.0001    **\<.0001**   **\<.0001**   **\<.0001**   
                                                                                                                                                                               
  IFN-*γ*       **0.86**      0.66          **0.80**      **0.95**   0.56          **0.73**   0.31          **0.72**      **0.79**   0.50          **0.81**      **0.82**      
  **\<.0001**   \<.0001       **\<.0001**   **\<.0001**   \<.0001    **\<.0001**   .0002      **\<.0001**   **\<.0001**   \<.0001    **\<.0001**   **\<.0001**                 
                                                                                                                                                                               
  GM-CSF        **0.86**      **0.72**      **0.89**      **0.87**   0.59          0.50       0.26          **0.77**      0.67       0.48          **0.79**                    
  **\<.0001**   **\<.0001**   **\<.0001**   **\<.0001**   \<.0001    \<.0001       .0015      **\<.0001**   \<.0001       \<.0001    **\<.0001**                               
                                                                                                                                                                               
  G-CSF         **0.77**      0.62          **0.71**      **0.86**   0.47          0.49       0.22          0.63          0.55       0.48                                      
  **\<.0001**   \<.0001       **\<.0001**   **\<.0001**   \<.0001    \<.0001       .0083      \<.0001       \<.0001       \<.0001                                              
                                                                                                                                                                               
  IL-12         **0.84**      0.53          **0.79**      **0.82**   0.45          **0.84**   0.35          **0.90**                                                           
  **\<.0001**   \<.0001       **\<.0001**   **\<.0001**   \<.0001    **\<.0001**   \<.0001    **\<.0001**                                                                      
                                                                                                                                                                               
  IL-10         **0.80**      0.68          **0.76**      **0.73**   0.69          0.63       0.23                                                                             
  **\<.0001**   \<.0001       **\<.0001**   **\<.0001**   \<.0001    \<.0001       .0237                                                                                       
                                                                                                                                                                               
  IL-7          0.61          0.34          0.61          **0.70**   0.35                                                                                                      
  \<.0001       \<.0001       \<.0001       **\<.0001**   \<.0001                                                                                                              
                                                                                                                                                                               
  IL-4          **0.88**      **0.70**      **0.81**                                                                                                                           
  **\<.0001**   **\<.0001**   **\<.0001**                                                                                                                                      
                                                                                                                                                                               
  IL-2          **0.83**      **0.77**                                                                                                                                         
  **\<.0001**   **\<.0001**                                                                                                                                                    
                                                                                                                                                                               
  IL-1Ra        **0.79**                                                                                                                                                       
  **\<.0001**                                                                                                                                                                  

\*For each pair of values, the correlation coefficient (*r*) is uppermost with the corresponding *P* value underneath.

Strong correlations (*r* ≥ 0.7) are highlighted in bold type, and moderate and weak correlations in plain type.

###### 

Correlations of RF, aMCV, and aCCP with cytokines, chemokines, and growth factors in the total cohort of RA patients (*n* = 140).

            RF       aMCV     aCCP
  --------- -------- -------- --------
  IL-1*β*   0.5199   0.3823   0.3264
  0.0001    0.0061   0.0207   
                              
  IL-1Ra    0.4193   0.4208   ns
  0.0024    0.0023            
                              
  IL-2      0.4737   0.4399   0.3607
  0.0005    0.0014   0.0101   
                              
  IL-4      0.6718   0.5277   0.5096
  0.0000    0.0001   0.0002   
                              
  IL-6      0.3970   0.4693   0.4346
  0.0043    0.0006   0.0016   
                              
  IL-7      0.5021   0.3244   0.3665
  0.0002    0.0215   0.0088   
                              
  IL-8      0.3407   ns       ns
  0.0155                      
                              
  IL-10     0.4339   0.4540   0.3450
  0.0016    0.0009   0.0142   
                              
  IL-12     0.5732   0.4526   0.4396
  0.0000    0.0010   0.0014   
                              
  IL-17A    0.2910   ns       ns
  0.0403                      
                              
  G-CSF     0.6254   0.5140   0.4969
  0.0000    0.0001   0.0002   
                              
  GM-CSF    0.6150   0.5639   0.4552
  0.0000    0.0000   0.0009   
                              
  IFN-*γ*   0.6561   0.5562   0.5473
  0.0000    0.0000   0.0000   
                              
  TNF       0.5667   0.4920   0.4120
  0.0000    0.0003   0.0029   
                              
  VEGF      0.4405   ns       ns
  0.0014                      
                              
  CCL2      0.3624   ns       ns
  0.0097                      
                              
  CCL4      0.3597   0.4444   0.3790
  0.0103    0.0012   0.0066   

RF: Rheumatoid factor, aCCP: anticyclic citrullinated peptide antibodies, aMCV: Antimutated citrullinated vimentin antibodies.

ns: not significant.

###### 

Correlations of VEGF with autoantibodies, circulating cytokines, and X-ray scores in the total cohort (*n* = 140) and HDA group (*n* = 63).

            Total             HDA
  --------- ----------------- ---------------
  RF        0.44 (0.0014)     0.60 (0.0023)
  SAA       ns                ns
  CRP       ns                ns
  aMCV      ns                0.59 (0.0023)
  aCCP      ns                0.67 (0.0003)
  IL-1*β*   0.29 (0.0433)     0.48 (0.0190)
  IL-1Ra    ns                0.41 (0.0474)
  IL-2      0.40 (0.0038)     0.61 (0.0014)
  IL-4      0.36 (0.0098)     0.65 (0.0006)
  IL-7      0.55 (\<0.0000)   0.65 (0.0006)
  IL-8      ns                0.41 (0.0448)
  IL-10     0.38 (0.0072)     0.46 (0.0246)
  IL-12     0.46 (0.0009)     0.60 (0.0021)
  G-CSF     0.31 (0.0306)     0.55 (0.0052)
  GM-CSF    0.37 (0.0086)     0.69 (0.0002)
  IFN-*γ*   0.37 (0.0082)     0.66 (0.0004)
  TNF       ns                0.53 (0.0078)
  CCL2      0.40 (0.0044)     ns
  CCL4      ns                0.56 (0.0044)
  Larsen    ns                0.42 (0.0409)

RF: Rheumatoid factor, SAA: Serum amyloid A, CRP: C-reactive protein, aCCP: anticyclic citrullinated peptide antibodies, aMCV: Antimodified citrullinated vimentin antibodies.

ns: not significant.

[^1]: Academic Editor: Tânia Fröde
